Deucravacitinib, CAS [[1609392-27-9]]

Produktübersicht

• Artikelname: Deucravacitinib, CAS [[1609392-27-9]]
• Artikelnummer: MCE-HY-117287
• Hersteller Artikelnummer: HY-117287
• Alternativnummer: MCE-HY-117287-1G,MCE-HY-117287-10MG,MCE-HY-117287-10MMX1ML,MCE-HY-117287-2MG,MCE-HY-117287-50MG,MCE-HY-117287-5MG,MCE-HY-117287-200MG,MCE-HY-117287-100MG,MCE-HY-117287-25MG,MCE-HY-117287-500MG
• Hersteller: MedchemExpress
• Kategorie: Biochemikalien
• Alternative Synonym: BMS-986165

Produktbeschreibung

Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDAs world first de novo deuterium, is available for study in moderate to severe plaque psoriasis[1][2].

Produkteigenschaften

• Molekulargewicht: 425.46
• Reinheit: 99.93
• CAS Nummer: [1609392-27-9]
• Formel: C20H19D3N8O3
• Target-Kategorie: IFNAR,Interleukin Related,Isotope-Labeled Compounds,JAK

Anwendungsbeschreibung

• Anwendungsbeschreibung: MCE Product type: Isotope-Labeled Compounds